State Street
PRME icon

State Street’s Prime Medicine PRME Stock Holding History

State Street’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.1M Buy
6,345,125
+1,249,615
+25% +$4.76M ﹤0.01% 2196
2025
Q4 		$17.7M Buy
5,095,510
+3,798,884
+293% +$16.9M ﹤0.01% 2337
2025
Q3 		$7.18M Buy
1,296,626
+57,289
+5% +$233K ﹤0.01% 2817
2025
Q2 		$3.06M Buy
1,239,337
+94,032
+8% +$145K ﹤0.01% 3155
2025
Q1 		$2.28M Sell
1,145,305
-8,876
-0.8% -$22.6K ﹤0.01% 3193
2024
Q4 		$3.37M Buy
1,154,181
+7,232
+0.6% +$25.4K ﹤0.01% 3123
2024
Q3 		$4.44M Buy
1,146,949
+43,086
+4% +$200K ﹤0.01% 3020
2024
Q2 		$5.67M Buy
1,103,863
+325,081
+42% +$1.97M ﹤0.01% 2866
2024
Q1 		$5.45M Buy
778,782
+19,024
+3% +$144K ﹤0.01% 2891
2023
Q4 		$6.73M Sell
759,758
-926,243
-55% -$7.14M ﹤0.01% 2792
2023
Q3 		$16.1M Buy
1,686,001
+1,080,802
+179% +$14M ﹤0.01% 2302
2023
Q2 		$8.87M Buy
605,199
+415,771
+219% +$5.8M ﹤0.01% 2706
2023
Q1 		$2.33M Buy
189,428
+74,582
+65% +$1.21M ﹤0.01% 3293
2022
Q4 		$2.13M Buy
+114,846
New +$2.07M ﹤0.01% 3353

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street's PRME Position: Q1 2026 in Review

State Street increased its Prime Medicine (PRME) stake by 25% in Q1 2026, buying an estimated $4.76M and bringing the position to 6,345,125 shares worth $22.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

State Street first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • State Street held 6,345,125 shares of Prime Medicine worth $22.1M as of Q1 2026.
  • State Street bought 1,249,615 Prime Medicine shares in Q1 2026, an estimated $4.76M.
  • Prime Medicine made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2196 holding.
  • State Street first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.